Podcast Summary: The Journal.

Episode: Fertility Inc.: The Embryo Editing Dinner
Date: March 27, 2026
Hosts: Ryan Knudsen, Jessica Mendoza
Produced by: The Wall Street Journal & Spotify Studios

Episode Overview

This episode explores the clandestine and controversial movement within Silicon Valley to pioneer human embryo gene editing—taking an inside look at key players, motivations, ethical debates, and the emergence of the company Preventive. The story centers on a private "Embryo Editing Dinner" among Silicon Valley elites and scientists, the ambitions of Coinbase CEO Brian Armstrong, and the secretive work of startups aiming to genetically engineer babies. The episode also contrasts embryo editing with the growing industry of embryo screening, raising questions about ethics, power, and where to draw societal lines.

Key Discussion Points & Insights

Setting the Scene: The Embryo Editing Dinner

[00:29 – 03:20]

• Location: A private room at Quince, an ultra-luxury restaurant in San Francisco.
• Attendees: Silicon Valley elites and top scientists.
• Central Figure: Brian Armstrong, Coinbase CEO, described as "wearing all black, kind of holding court" (Jessica Mendoza, [01:07]).
• Main Question: Not "should we" or "can we" edit embryos, but “we are going to edit an embryo.” (Jessica Mendoza, [02:25])

“How might they bring the powerful and highly debated medical technology known as embryo editing to fruition?” – Jessica Mendoza, [00:22]

• What’s at Stake?

“Life as we know it.” – Jessica Mendoza, [02:43]

The State of Embryo Editing Technology

[05:02 – 08:28]

• CRISPR and Gene Editing: Techniques now allow precise editing of embryonic DNA.
• The “One Known Case”:
  • In 2018, Chinese scientist He Jiankui edited embryos to make babies immune to HIV, resulting in global outrage and his imprisonment.
  • Concerns about heritable edits and unintended "off target consequences" ([07:27]).
• Global Response:
  • A coalition in 2025 called for a 10-year moratorium on bringing edited embryos to term unless a global regulatory framework is created.

The Motivation & Risks

[09:12 – 11:24]

• Brian Armstrong’s Vision: Publicly advocates gene editing to reduce risks of diseases like heart disease, osteoporosis. Also interested in non-therapeutic "enhancements".
  • Armstrong’s reference to “the Gattaca stack”—a nod to the film's eugenic sci-fi future ([10:37–10:55]).
• Ethical Fears:
  • Slippery slope from disease prevention to “designer babies” and eugenics.
  • Potential for social stratification by enhancement.

“There could be some group of people that are enhanced and therefore smarter, better, stronger, faster ... and then suddenly you have, like, a new class of human.” – Ryan Knudsen, [08:28]

From Talk to Action: The Preventive Case

[12:09 – 19:33]

• Discovery: Journalist Emily Glaser uncovers the formation of Preventive, a secretive embryo editing startup with investments from Sam Altman (OpenAI CEO) and Brian Armstrong.
  • Company Operations: Allegedly sought to work in the UAE, where regulations are more permissive; reportedly identified an interested couple (Preventive denied this).
  • Public Statement: Preventive later emerges from stealth, claiming their mission is to “determine whether the newest generation of gene editing technologies can be used safely and responsibly to correct devastating genetic conditions for future children.” ([17:08])
  • Company Growth: Hired significant scientific talent, signaling ongoing, real-world work.

“This thing is real.” – Jessica Mendoza, on learning of Preventive's actual existence, [12:35]

• Denials and Statements: Preventive CEO Lucas Harrington denies working with a couple, states focus is still on research ([17:49]). Armstrong and Altman confirm investments and express interest in curing genetic disease ([18:26]).

Embryo Screening: The Already-Here Reality

[19:54 – 23:43]

• Screening vs. Editing: While editing is illegal in the US, screening for existing embryos is available and rapidly expanding.
  • Companies like Orchid and Nucleus: Offer screening for disease risk (Orchid: $2,500/embryo) and for appearance/intelligence traits (Nucleus: $10,000+, promoted as “have your best baby”).
  • Brian Armstrong is also an investor in this space.
  • Some services market eugenic implications, and their predictive accuracy is questioned.

"We give you the full range of Insights there is to know about your future child." – Nucleus CEO, [22:10]

• Moral and Societal Implications:
  • Technologies tempt parents, raise issues of equity and societal pressure to “optimize” offspring.
  • Where to draw the line between therapy and enhancement remains contentious.

“The question, though, is where do you draw the line? And there’s just so much morality tied up in that.” – Ryan Knudsen, [23:36]

Silicon Valley vs. Science: Culture Clash

[23:48 – 24:57]

• Tech Culture: “Just try it and see what happens,” with a philosophy to “ask for forgiveness later” ([24:25–24:28]).
• Scientific Caution: Calls for comprehensive study, safety, and ethical debate—“you can't do that with a human life.”

“It’s almost like comparing the perhaps lowercase C conservative nature of academia to the other extreme of tech entrepreneurs.” – Jessica Mendoza, [24:00]

Notable Quotes & Memorable Moments

• “It was basically called the embryo editing dinner.” – Jessica Mendoza, [01:58]
• “We are going to edit an embryo.” – Jessica Mendoza, [02:25]
• “Embryo editing with the intention of bringing a baby to term is illegal in many countries around the world, including the US.” – Ryan Knudsen, [08:28]
• “He has made comparisons to the movie Gattaca, the sci fi classic.” – Jessica Mendoza, [09:57]
• “One plan that Brian Armstrong had floated was for a venture to work in secret and then reveal a healthy genetically engineered baby before the scientific and medical establishment had a chance to object. And it was almost like this leap that was meant to shock the world into acceptance.” – Jessica Mendoza, [11:24]
• “This thing is real.” – Jessica Mendoza, [12:35]
• “Some offer eye color, baldness. It's not just cosmetic. There's also more screening for different diseases beyond what you could traditionally get.” – Jessica Mendoza, [21:02]
• “I think basically sex is for fun and embryo screening is for babies.” – Orchid CEO, [21:32]
• “Absolute… I think that's a big question, right? Who's gonna be that person to say, why wouldn't you want to help eradicate diseases?” – Jessica Mendoza, [23:10]
• “One group wants to study every last thing and the other one wants to rip off the band aid and start doing it.” – Jessica Mendoza, [24:00]

Timeline of Important Segments

• [00:29–03:20] – The Embryo Editing Dinner & context
• [05:02–08:28] – Science, history, ethics of gene editing
• [09:12–11:24] – Brian Armstrong, Silicon Valley’s ambitions
• [12:09–19:54] – Formation & operation of Preventive
• [19:54–23:43] – Embryo screening industry
• [23:48–24:57] – Silicon Valley vs. academia

Final Thoughts

Silicon Valley’s drive to push boundaries in human gene editing is at an inflection point, illustrated by secretive dinners, stealth startups, and public investment by powerful tech leaders. The episode frames the conversation as a culture clash between the fast-moving, risk-taking optimism of technology entrepreneurs and the deliberate, ethically-cautious pace of science and medicine. With embryo screening technologies already in use and gene editing looming on the horizon, society faces urgent questions about what we should allow—and who gets to decide.

For more in the Fertility Inc. series, check out The Journal's Spotify playlist linked in the show notes.